Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes
Authors' conclusion
This population-based cohort study suggests that SGLT2i was not associated with an increased rate of incident fractures compared with DPP4i and GLP1RA, separately, among postmenopausal individuals with type 2 diabetes.
Study context
- Population
- Postmenopausal individuals (aged ≥45 years) with type 2 diabetes, nationwide claims data of Korea, 2013–2020two separate comparison cohorts
- Exposure
- SGLT2i vs DPP4i and vs GLP1RA, separately
- DPP4in = 332,004reference
- GLP1RAn = 8,177reference
- Outcome
- Overall fractures (vertebral, hip, humerus and distal radius)
Methodological detailsactive-comparator, new-user, nationwide claims data, propensity score fine stratification, weighted Cox models
- Active-comparator
- New-user
- Nationwide claims data
- Propensity score fine stratification
- Weighted Cox models
Main finding
As reported in the abstract
Overall fractures
Weighted hazard ratio (95% CI)
SGLT2i vs DPP4i37 530 SGLT2ivs 332 004 DPP4i new users
0.78(0.72–0.84)
SGLT2i vs GLP1RA111 835 SGLT2ivs 8177 GLP1RA new users
0.92(0.68–1.24)
Observational data: associations, not effects.
Further findings
Subgroup and sensitivity analyses
- Consistent results with main analysis
Original publication
Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes. JAMA Netw Open. Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →